New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 18, 2013
10:45 EDTVPHM, SKT, RDEN, TDG, PG, CFNL, TWGP, NRG, GBL, CLX, AYI, JRCC, EXC, ARQL, JOY, INTU, CAT, BMRNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Acuity Brands (AYI) downgraded to Neutral from Buy at UBS... ArQule (ARQL) downgraded to Neutral from Buy at Citigroup... BioMarin (BMRN) downgraded to Hold from Buy at Stifel... Caterpillar (CAT) downgraded to Neutral from Outperform at RW Baird... Clorox (CLX) downgraded to Underweight from Equal Weight at Barclays... Exelon (EXC) downgraded to Sector Perform from Outperform at RBC Capital... GAMCO Investors (GBL) downgraded to Underperform from Neutral at BofA/Merrill... Intuit (INTU) downgraded to Underweight from Equal Weight at Morgan Stanley... James River Coal (JRCC) downgraded to Underweight from Hold at BB&T... Joy Global (JOY) downgraded to Neutral from Outperform at RW Baird... NRG Energy (NRG) downgraded to Neutral from Conviction Buy at Goldman... Procter & Gamble (PG) downgraded to Equal Weight from Overweight at Barclays... Tanger Factory (SKT) downgraded to Hold from Buy at Jefferies... Tower Group (TWGP) downgraded to Market Perform from Outperform at FBR Capital... TransDigm (TDG) downgraded to Sector Perform from Outperform at RBC Capital... ViroPharma (VPHM) downgraded to Neutral from Buy at BofA/Merrill... Cardinal Financial (CFNL) downgraded to Neutral at Boenning & Scattergood... Elizabeth Arden (RDEN) downgraded to Neutral from Buy at B. Riley.
News For AYI;BMRN;ARQL;CLX;CAT;EXC;GBL;INTU;JRCC;NRG;JOY;PG;SKT;TWGP;TDG;VPHM;CFNL;RDEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 20, 2015
19:05 EDTINTUIntuit raises quarterly dividend 20% to 30c per share
Announced in the company's Q4 earnings release, Intuit said it has received board approval for a 30c per share dividend for fiscal Q1, payable October 19. The dividend represents a 20% increase versus last year and reflects the company's "large and growing cash position, as well as more recurring and predictable revenue streams."
19:02 EDTINTUOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTINTUIntuit to divest Demandforce, QuickBase, Quicken, sees negative impact in FY16
Subscribe for More Information
16:07 EDTINTUIntuit reports Q4 QuickBooks Online subscribers 1.08M
Subscribe for More Information
16:04 EDTINTUIntuit sees FY16 adjusted EPS $3.40-$3.45, consensus $3.82
Subscribe for More Information
16:03 EDTINTUIntuit sees Q1 adjusted EPS (4c)-(3c), consensus 6c
Subscribe for More Information
16:01 EDTINTUIntuit reports Q4 adjusted EPS (5c), consensus (12c)
Subscribe for More Information
14:42 EDTINTUNotable companies reporting after market close
Subscribe for More Information
09:08 EDTAYIEnergy Focus price target raised to $23 from $16 at Roth Capital
Subscribe for More Information
August 19, 2015
16:06 EDTBMRNBioMarin receives rare pediatric disease designation from FDA for drisapersen
Subscribe for More Information
10:00 EDTINTUOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:17 EDTBMRN'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTBMRNFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
08:21 EDTINTUIntuit August volatility elevated into Q4 and outlook
Intuit August call option implied volatility is at 56, September is at 26 compared to its 52-week range of 16 to 42 suggesting large price movement into the expected release of Q4 results on Aug 20.
07:49 EDTINTUIntuit coverage assumed with an Equal Weight at Morgan Stanley
Subscribe for More Information
07:08 EDTEXCExelon called 'clear value' ahead of PJM auction results at Deutsche Bank
Subscribe for More Information
07:01 EDTINTUIntuit upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
August 17, 2015
07:40 EDTCATUBS to hold a tour
Midwest Construction & Farm Tour travels throughout Illinois and Iowa on August 17-18.
August 16, 2015
12:23 EDTPGTrouble ahead for Procter & Gamble, others as Chinese yuan falls, Barron's says
Subscribe for More Information
August 14, 2015
16:57 EDTNRGSoros gives quarterly update on stakes, increases Facebook position
NEW STAKES: Time Warner Cable (TWC), Schwab (SCHW), Alcoa (AA), NRG Energy (NRG), and Pacira (PCRX). INCREASED STAKES: Facebook (FB), Monsanto (MON), Nextera (NEE), Qunar (QUNR), and Rovi (ROVI). DECREASED STAKES: Alibaba (BABA), General Motors (GM), Motorola Solutions (MSI), EQT Corp (EQT), and Noble Energy (NBL). LIQUIDATED STAKES: Cenovus (CVE), Kite Pharma (KITE), Tempur Sealy (TPX), CF Industries (CF), and Suncor Energy (SU).
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use